Home
About
Overview
Sharing Data
ORCID
Help
History (4)
A multi-institutional partnership catalyzing the commercialization of medical devices and biotechnology products.
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
Association of Advance Care Planning Visits With Intensity of Health Care for Medicare Beneficiaries With Serious Illness at the End of Life.
FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape.
See All 4 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape.
Mittal K, Joshi M. FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape. Med. 2024 Mar 08; 5(3):176-178.
View in:
PubMed
subject areas
Carcinoma, Transitional Cell
Humans
Immunotherapy
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Urinary Bladder Neoplasms
authors with profiles
Kriti Mittal MD